FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SOUTH SAN FRANCISCO, Calif., March 14, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences.
Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 8:35 AM Eastern Time at the Westin Grand Central Hotel in New York City.
Mr. Quinn will also present at the Needham & Company’s 17th Annual Healthcare Conference on Tuesday, March 27, 2018 at 8:00 AM Eastern Time at the Westin Grand Central Hotel in New York City.
Live webcasts of the presentations will be available on the Sunesis website at http://ir.sunesis.com. A replay of each webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 | Willie Quinn Sunesis Pharmaceuticals Inc. 650-266-3716 | ||
